Abstract
Binge eating disorder (BED) has limited therapeutic options. Repetitive transcranial magnetic stimulation (rTMS) is a modulation technique of cortical excitability that has shown good results in treating certain psychiatric disorders by correcting dysfunctional cortical regions. We hypothesize that rTMS could be an alternative therapy for BED through potential modulation action on frontostriatal abnormalities and dopaminergic pathways noted by neuroimaging. We report the case of a young woman presenting refractory BED and comorbid depression treated with 20 sessions of rTMS for 30 minutes over the left dorsolateral prefrontal cortex at 10 Hz for about a month (2400 stimuli per day). She answered two self-report questionnaires, the Binge Eating Scale (BES) and the Beck Depression Inventory (BDI). Before rTMS treatment, the BES score was 38, and the BDI score was 42. Three days after rTMS treatment, the BES score was 27 and the BDI score was 23, and the patient referred to no binge eating episodes for that week. Therefore, rTMS could offer a new option of treatment for BED and comorbid depression.
Keywords: Binge eating disorder, depression, dopamine, frontostriatal pathways, obesity, repetitive transcranial magnetic stimulation.
CNS & Neurological Disorders - Drug Targets
Title:High-Frequency rTMS to Treat Refractory Binge Eating Disorder and Comorbid Depression: A Case Report
Volume: 13 Issue: 5
Author(s): Tathiana Pires Baczynski, Carolina Hanna de Aquino Chaim, Bruno Palazzo Nazar, Mauro Giovanni Carta, Oscar Arias-Carrion, Adriana Cardoso Silva, Sergio Machado and Antonio Egidio Nardi
Affiliation:
Keywords: Binge eating disorder, depression, dopamine, frontostriatal pathways, obesity, repetitive transcranial magnetic stimulation.
Abstract: Binge eating disorder (BED) has limited therapeutic options. Repetitive transcranial magnetic stimulation (rTMS) is a modulation technique of cortical excitability that has shown good results in treating certain psychiatric disorders by correcting dysfunctional cortical regions. We hypothesize that rTMS could be an alternative therapy for BED through potential modulation action on frontostriatal abnormalities and dopaminergic pathways noted by neuroimaging. We report the case of a young woman presenting refractory BED and comorbid depression treated with 20 sessions of rTMS for 30 minutes over the left dorsolateral prefrontal cortex at 10 Hz for about a month (2400 stimuli per day). She answered two self-report questionnaires, the Binge Eating Scale (BES) and the Beck Depression Inventory (BDI). Before rTMS treatment, the BES score was 38, and the BDI score was 42. Three days after rTMS treatment, the BES score was 27 and the BDI score was 23, and the patient referred to no binge eating episodes for that week. Therefore, rTMS could offer a new option of treatment for BED and comorbid depression.
Export Options
About this article
Cite this article as:
Baczynski Pires Tathiana, Chaim Hanna de Aquino Carolina, Nazar Palazzo Bruno, Carta Giovanni Mauro, Arias-Carrion Oscar, Silva Cardoso Adriana, Machado Sergio and Nardi Egidio Antonio, High-Frequency rTMS to Treat Refractory Binge Eating Disorder and Comorbid Depression: A Case Report, CNS & Neurological Disorders - Drug Targets 2014; 13 (5) . https://dx.doi.org/10.2174/1871527313666140307154823
DOI https://dx.doi.org/10.2174/1871527313666140307154823 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Leptin Plasma Levels in the General Population: Influence of Age, Gender, Body Weight and Medical History
Protein & Peptide Letters Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review
Current Neuropharmacology Medicinal Chemistry of Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Empathy and Burnout: Implications for those who Care
Current Psychiatry Reviews Acknowledgements to Reviewers:
Central Nervous System Agents in Medicinal Chemistry Effect of Oxidative Stress on the Pharmacokinetics of Clomipramine in Rats Treated with Ferric-Nitrilotriacetate
Drug Metabolism Letters Nicotine Effects on Human Affective Functions: A Systematic Review of the Literature on a Controversial Issue
CNS & Neurological Disorders - Drug Targets Prediction of Drug-Drug Interactions Related to Inhibition or Induction of Drug-Metabolizing Enzymes
Current Topics in Medicinal Chemistry Immune System Induction of Nerve Growth Factor in an Animal Model of Multiple Sclerosis: Implications in Re-Myelination and Myelin RepairATION AND MYELIN REPAIR
CNS & Neurological Disorders - Drug Targets Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry A Review of Developments in Brain Stimulation and the Treatment of Psychiatric Disorders
Current Psychiatry Reviews Bio-AIMS Collection of Chemoinformatics Web Tools based on Molecular Graph Information and Artificial Intelligence Models
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Chronic Royal Jelly Administration Induced Antidepressant-Like Effects Through Increased Sirtuin1 and Oxidative Phosphorylation Protein Expression in the Amygdala of Mice
Current Molecular Pharmacology The Role of Annexin A1 and Formyl Peptide Receptor 2/3 Signaling in Chronic Corticosterone-Induced Depression-Like behaviors and Impairment in Hippocampal-Dependent Memory
CNS & Neurological Disorders - Drug Targets Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Glutathione System as an Attractive Therapeutic Target
Drug Design Reviews - Online (Discontinued)